Product Information
MYFORTIC 180 MG TABLET is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $7.4331 per EA under NDC 00078038566. Its NADAC has been published 532 times since Nov 28, 2013.
FDA first approved this application on Feb 27, 2004. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the mycophenolic acid market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
180 mg/1
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078038566
Classification
Brand
Dosage Form
TABLET, DELAYED RELEASE
Route
ORAL
Effective Date
7/8/2026
Active Ingredients
MYCOPHENOLATE SODIUMApproval Type
New Drug (NDA)
FDA Application
NDA050791FDA Approved
2/27/2004
TE Code
AB
On Market Since
2/27/2004
Pharmacological Classes
Price Statistics
The NADAC for MYFORTIC 180 MG TABLET has been published 532 times since Nov 28, 2013, and over the history we have for it it has risen 81.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $7.4331 per EA |
|---|---|
| All-time high | $7.4331 (Sep 30, 2026) |
| All-time low | $4.0666 (May 21, 2014) |
| 52-week high | $7.4331 |
| 52-week low | $7.1998 |
| Median price | $4.9954 |
| Average price | $5.3272 |
| Largest weekly change | +19.8% (Jul 17, 2024) |
| Weeks tracked | 532 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novartis Pharmaceuticals Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
mycophenolic acid market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antimetabolite Immunosuppressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MYFORTIC 180 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for MYFORTIC 180 MG TABLET, manufactured by Novartis Pharmaceuticals Corporation, is $7.4331 per EA (NDC 00078038566), effective Sep 30, 2026.
How has the price of MYFORTIC 180 MG TABLET changed over time?
Over the history we have for it, the NADAC for MYFORTIC 180 MG TABLET has risen 81.4%. It has been tracked across 532 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for MYFORTIC 180 MG TABLET?
Since Nov 28, 2013, the NADAC for MYFORTIC 180 MG TABLET has ranged from a low of $4.0666 (May 21, 2014) to a high of $7.4331 (Sep 30, 2026), with a median of $4.9954 per EA.
Are there cheaper alternatives to MYFORTIC 180 MG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, MYCOPHENOLIC ACID DR 180 MG TB, is $0.0996 per EA — about 99% below MYFORTIC 180 MG TABLET.
Who manufactures MYFORTIC 180 MG TABLET?
MYFORTIC 180 MG TABLET (NDC 00078038566) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.